PharmaDossierIndependent biopharma information, guidance, and source-cited analysis.

PHARMApharmadossier

Topic

JAK Inhibitor

JAK inhibitor labels, boxed warnings, step therapy, immunology positioning, and access restrictions.

3 articles·Lives underPricing & Access Evidence·Last updated 2026-06-14

Evidence· June 14, 2026 · 12 min read

JAK inhibitors in FAERS: 242,498 adverse-event reports by the numbers

By Ran Chen#Real-World Evidence #Label Warnings #Postmarketing Requirements

Pipeline· June 8, 2026 · 10 min read

Veterinary JAK inhibitors Apoquel to Numelvi: FDA pathway compared

By Ran Chen#JAK Inhibitor #FDA Approval #Veterinary Medicine

Pricing & Access· May 24, 2026 · 12 min read

JAK inhibitor access landscape: Rinvoq, Xeljanz, Olumiant, Leqselvi, and Cibinqo in 2026

By Ran Chen#JAK Inhibitor #Immunology #Coverage Access